DAX ®12.168,74+0,21%TecDAX ®2.913,05+1,41%S&P FUTURE2.842,30-0,53%Nasdaq 100 Future7.367,75-0,84%
finanztreff.de

Press Release: Helsinn nominated as a Swiss Biotech Success Story 2019/2020 by the Swiss Biotech Association

| Quelle: Dow Jones Newsw... | Lesedauer etwa 3 min. | Text vorlesen Stop Pause Fortsetzen


Helsinn nominated as a Swiss Biotech Success Story 2019/2020 by the
Swiss Biotech Association

Switzerland, May 7, 2019: Helsinn, a Swiss pharmaceutical group focused
on building quality cancer care products, today announces that it is one
of the companies to have been nominated as one of the Swiss Biotech
Association's Biotech Success Stories for the period 2019/2020.

Helsinn was nominated alongside Actelion and Debiopharm, as well as
three foundations Venture Foundation, Venturelab and Venture Kick. For
the first time, the nominees include an individual: Prof. Dr. Werner
Arber, who was awarded the 1978 Nobel Prize in Physiology or Medicine.

Each year, the Swiss Biotech Association presents companies with the
"Swiss Biotech Success Stories" awards in recognition of outstanding
achievements.

Biogen, Okairos, Roche Glycart, Selexis, and Vifor Fresenius Medical
Care Renal Pharma received the award at this year's Swiss Biotech Day
after being nominated in 2018.

Swiss Biotech Association's press release is available
https://www.globenewswire.com/Tracker?data=ED01VtzRnmajBmJ7x_3Z0XWasGy_at8saHhti59SHclZ3CF_HpfB-2-W-QFeszY0kDOlTGu7O8pvfM2yOZoYdUYhMEUrrpgCyPPtB6SYIGWPT-u8allmMD5fIAR3Wp2an7LqgZhm_l_sowHLi-cwv7rD0xQBfjOKEPplpumin2-PWOq0rSOAgJu9PNCkHpRRfKtveoaMmtgphwWpJC7IpQ
here.

Riccardo Braglia, Helsinn Group Vice Chairman and CEO, commented: "We're
delighted to be part of the continued success of the Swiss Biotech
industry. Switzerland is a world-leading hub for biopharma thanks to a
unique set of factors: diversity, the excellence of the science base,
strong infrastructure and excellent technology transfer and a
collaborative approach, leading to a healthy pipeline of scientific
development. These are all factors which are highly prized at Helsinn
and we are very pleased that the Swiss Biotech Association has
recognised us for our strength."

ENDS

About the Helsinn Group

Helsinn is a privately owned pharmaceutical group with an extensive
portfolio of marketed cancer care products and a robust drug development
pipeline. Since 1976, Helsinn has been improving the everyday lives of
patients, guided by core family values of respect, integrity and
quality. The Group works across pharmaceuticals, biotechnology, medical
devices and nutritional supplements and has expertise in research,
development, manufacture and the commercialization of therapeutic and
supportive care products for cancer, pain and inflammation and
gastroenterology. In 2016, Helsinn created the Helsinn Investment Fund
to support early-stage investment opportunities in areas of unmet
patient need. The company is headquartered in Lugano, Switzerland, with
operating subsidiaries in Switzerland, Ireland, the U.S., Monaco, and
China, as well as a product presence in approximately 190 countries
globally.

For more information, please visit
https://www.globenewswire.com/Tracker?data=5uK3IFyV22hrRJQswIb663Hf-x6GkONuNVyaoLwA63JGidXWH57ggX1-OPUp-_nCVtmESwFZHZNpg-IyvR4Itw
www.helsinn.com

For further information, please contact:

Helsinn Group Media Contact

Paola Bonvicini

Group Head of Communication

Lugano, Switzerland

Tel: +41 (0) 91 985 21 21

Info-hhc@helsinn.com
https://www.globenewswire.com/Tracker?data=IbEp2oy8YLFH74x7AeqLrmp38oiOrzJA7lzuBUUlw5w0nwx0H2l_eodXUXWIPz_UHFaj2NCZ4Iz3YiFIsVRgXZG5QlO_MZZ4AuFsz_ffuV4=


For more information, please visit
https://www.globenewswire.com/Tracker?data=5uK3IFyV22hrRJQswIb66xoiaCGYsFMlp0OYeokkjoBH1nLHgqEm50MMuCoo2AtQ_YsBWRpDaqAAFZVubSj51g
www.helsinn.com and follow us on
https://www.globenewswire.com/Tracker?data=wHFh4yJTYCuqaiJGKSnVTxgdoM7dU1t7rpHbHhrANJf-RjweQisQp1A94VLsIEEPD1Lo1lrOHZFhqDZcJZdrsQ
Twitter,
https://www.globenewswire.com/Tracker?data=8JuPx44NjIENWM5S_-9O-pXWksmUAp8f1imo_Ods9GIToSjhvxok5R0NXM-WdPTi1cDfFZ7cVDURk2wcxAdR117Kj416dBkmjBh4aRVJSRM=
LinkedIn and
https://www.globenewswire.com/Tracker?data=_4stSCi7l_GStFblhOchTBsRHTkhJPPJEvaoXX_sRQxcbNSe37nQgAdY7cfCXebL-x_zfzWqVwrWmPFIZHyjHA
Vimeo





(END) Dow Jones Newswires

May 07, 2019 11:20 ET ( 15:20 GMT)
Werbung

Das könnte Sie auch interessieren

Weitere Nachrichten

Quelle: Dow Jones Newswire Web
08:34 DGAP-DD: 7x7 Energiewerte Deutschland II. GmbH & Co. KG deutsch
08:32 EUREX/DAX-Future baut Minus im Verlauf aus
08:31 Altmaier will Vorschlag für vollständige Soli-Abschaffung vorlegen
08:30 DGAP-DD: init innovation in traffic systems SE english
08:30 DGAP-DD: init innovation in traffic systems SE deutsch
08:30 DGAP-News: René Zahnd - CEO der Swiss Prime Site AG - wird Mitglied des Aufsichtsrates der DIC Asset AG
08:30 PRESS RELEASE: René Zahnd - CEO of Swiss Prime Site AG - to Join Supervisory Board of DIC Asset AG
08:27 TRENDUMFRAGE/DAX zum Schluss 0,7 Prozent niedriger erwartet
08:14 Konsum, Investitionen und Exporte stützen deutsches Wachstum im 1Q
08:03 Original-Research: EQS Group AG (von GSC Research GmbH): Halten
Rubrik: Finanzmarkt
08:42 ROUNDUP: Flixtrain fährt nun auch zwischen Berlin und Köln
08:34 DGAP-DD: 7x7 Energiewerte Deutschland II. GmbH & Co. KG (deutsch)
08:31 ROUNDUP 2: Deutsche Wirtschaft erholt sich - Wachstum zum Jahresanfang
08:30 DGAP-DD: init innovation in traffic systems SE (deutsch)
08:30 DGAP-News: René Zahnd - CEO der Swiss Prime Site AG - wird Mitglied des Aufsichtsrates der DIC Asset AG (deutsch)
08:29 KORREKTUR/ROUNDUP: Harte Fronten im Koalitionsstreit um Grundrente
08:28 Novartis verspricht Investoren steigende Dividende im Konzernumbau
08:27 'HB': Umstrittene Listen mit Monsanto-Kritikern sorgen für Zoff bei Bayer
08:25 ROUNDUP: Deutsche Wirtschaft wächst wieder - starke Binnennachfrage
08:22 Aktien Frankfurt Ausblick: Vorsichtige Dax-Anleger haben wieder die Oberhand
Werbung

News-Suche

Suchbegriff:
Werbung

Werbung
Börse Stuttgart Anlegerclubschliessen
Börse Stuttgart

Wir machen Sie fit für die Börse!

Aktuelle Nachrichten, umfangreiche
Hintergrundinformationen und essentielles
Finanzwissen rund um das Thema Börse.

Jetzt kostenfrei zum Anlegerclub anmelden.
Diese Seite empfehlenschliessen
Interessant, oder?
Teilen Sie diese Seite auf Facebook oder Twitter
Aktuelle Umfrageschliessen
Dietmar Zetsche verlässt Daimler - nach vier Jahrzehnten. Er hinterlässt viele Baustellen. Das Unternehmen befindet sich im Umbruch. Wird Daimler die Herausforderungen stemmen können?
Jetzt abstimmen!
Alle Umfragen ansehen